Syneos Health has launched its Patient Voice Consortium. The Consortium is a cross-functional hub designed to share knowledge, resources, and relationships. These efforts seek to define best practices for gaining patient insights to pressure-test, problem-solve and co-create clinical trial design, communications, stakeholder education, access initiatives and launch strategies.
The Consortium builds on Syneos Health knowledge including patient journey mapping, behavioral science referenced in the Syneos Health subject matter authored book Why We Resist and ongoing DE&I efforts designed to expand access and diversity in clinical trials. The Consortium seeks to learn from the widest range of patient communities possible. Inclusive, transparent methodologies, rooted in shared purpose and bidirectional communications, will guide Consortium efforts.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.